背景:尿路感染(UTI)是最常见的细菌感染。根据“膀胱炎”的要求,RSCI系统中有12,067种出版物(例如图书馆)截至2023年10月08日,在Pubmed中筛选了16,332篇文章。这是膀胱炎问题远未解决的证据。
方法:共425例细菌性阴道病患者和77例慢性复发性膀胱炎患者纳入研究。在所有患者中,通过分子遗传学检测评估了阴道生物注射病.检查包括填写俄语版本的急性膀胱炎症状评分(ACSS),尿液分析,和尿液培养。此外,使用激光多普勒血流仪(LDF)测量局部微循环。检查后,患者接受基本治疗,并随机分为三组.在对照组(n=17)中,只有基础治疗,包括磷霉素3.0一次在晚上+furagin100毫克饭后,每天3次,共5天。在主要的第1组中,有29名妇女接受了基础治疗加上超级淋巴栓剂10个单位,每天2次,持续10天。在主要第2组中,31例患者接受了基础治疗加上栓剂Superlymiry10个单位(早晨直肠)和AcylactDuo(晚上阴道)10天。
结果:在425例细菌性阴道病患者中,78(18.3%)抱怨各种泌尿系统疾病,但只有21名女性(4.9%的阴道菌群失调患者和26.9%的排尿困难患者)被诊断为膀胱炎.在所有情况下,这是慢性疾病的恶化。在77例慢性膀胱炎患者中,正常阴道菌群最初存在于32例(41.6%),细菌性阴道病45例(58.4%)。治疗后,所有组的患者均有阳性结果.仅接受基础治疗的15名妇女(88.2%)完全根除了病原体;在主要的第1组和第2组中,有27例(93.1%)和28例(90.3%)未检测到尿路病原体,分别。在对照组中,阴道菌群正常的患者比例基本保持不变(41.2%[n=7]vs.47.1%[n=8])。在主要第1组中,阴道菌群正常的患者比例几乎翻了一番:从41.4%(n=12)到79.3%(n=23)。在第2组中,87.1%的病例发现阴道菌群恢复。
结论:根据我们的数据,只有4.9%的细菌性阴道病患者被诊断为慢性膀胱炎,然而,58.4%的慢性膀胱炎患者存在阴道菌群失调。抗菌肽和细胞因子的复合物的使用显着增加了治疗的双向效果。栓剂超淋巴与AcylactDuo的阴道使用相结合,可以获得最佳结果。
BACKGROUND: Urinary tract infections (UTIs) are among the most common bacterial infections. At the request \"cystitis\", there are 12,067 publications in the RSCI system (e.library) as of 10/08/2023 and 16,332 articles were screened in the Pubmed. This is evidence that the problem of cystitis is far from being resolved.
METHODS: A total of 425 patients with bacterial vaginosis and 77 women with chronic recurrent cystitis were included in the study. In all patients, the vaginal biocenosis was assessed through molecular genetic testing. The examination included filling out the Russian version of the Acute Cystitis Symptom Score (ACSS), urinalysis, and urine culture. In addition, local microcirculation was measured using laser Doppler flowmetry (LDF). After examination, patients were prescribed basic therapy and randomly assigned to one of three groups. In a control group (n=17), only basic therapy, consisting of fosfomycin 3.0 once at night + furagin 100 mg after meals 3 times a day for 5 days was prescribed. In the main group 1, 29 women received basic therapy plus Superlymph suppositories 10 units 2 times a day vaginally for 10 days. In the main group 2, 31 patients received basic therapy plus suppositories Superlymph 10 units (rectally in the morning) and Acylact Duo (vaginally in the evening) for 10 days.
RESULTS: Among 425 patients with bacterial vaginosis, 78 (18.3%) complained of various urinary disorders, but only 21 women (4.9% of those with vaginal dysbiosis and 26.9% with dysuria) had a diagnosis of cystitis. In all cases, it was an exacerbation of a chronic disease. Among 77 patients with chronic cystitis, normal vaginal flora was initially present in 32 patients (41.6%), and bacterial vaginosis was found in 45 (58.4%) cases. After therapy, positive results were noted in patients of all groups. Complete eradication of the pathogen occurred in 15 women (88.2%) who received only basic therapy; in the main groups 1 and 2, uropathogens were not detected in 27 (93.1%) and 28 (90.3%) cases, respectively. In the control group, the proportion of patients with normal vaginal flora remained virtually unchanged (41.2% [n=7] vs. 47.1% [n=8]). In the main group 1, the proportion of patients with normal vaginal flora almost doubled: from 41.4% (n=12) to 79.3% (n=23). In main group 2, restoration of vaginal flora was noted in 87.1% of cases.
CONCLUSIONS: According to our data, only 4.9% of patients with bacterial vaginosis were diagnosed with chronic cystitis, however, 58.4% of patients with chronic cystitis had vaginal dysbiosis. The use of a complex of antimicrobial peptides and cytokines has significantly increased the bidirectional effect of therapy. Suppositories Superlymph in a combination with vaginal use of Acylact Duo allow to obtain the best results.